ARDELYX INC. - COMMON STOCK

Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023

04 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

28 Sep 2023 07:02:00 By Nasdaq GlobeNewswire

Tenapanor for Hyperphosphatemia Approved in Japan

25 Sep 2023 03:15:13 By Nasdaq GlobeNewswire

Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023

11 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference

08 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

07 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance

02 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

27 Jul 2023 15:05:00 By Nasdaq GlobeNewswire

Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023

26 Jul 2023 06:55:00 By Nasdaq GlobeNewswire

Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference

20 Jul 2023 15:05:00 By Nasdaq GlobeNewswire

Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

13 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

29 Jun 2023 15:09:08 By Nasdaq GlobeNewswire

Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase

05 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Ardelyx to Present at the Jefferies 2023 Healthcare Conference

31 May 2023 07:00:00 By Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

23 May 2023 15:05:00 By Nasdaq GlobeNewswire

Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)

17 May 2023 06:30:00 By Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

15 May 2023 15:05:01 By Nasdaq GlobeNewswire

Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

09 May 2023 07:00:02 By Nasdaq GlobeNewswire

Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update

03 May 2023 15:02:00 By Nasdaq GlobeNewswire

Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference

01 May 2023 07:00:01 By Nasdaq GlobeNewswire